We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current TRVI market cap is 314.38M. The company's latest EPS is USD -0.3781 and P/E is -10.76.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -9.05M | -8.93M | -11.91M | -13.29M | -14.09M |
| Net Income | -7.7M | -7.82M | -10.9M | -12.35M | -13.24M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -26.65M | -32.49M | -32.48M | -29.91M | -33.92M |
| Net Income | -25.22M | -32.76M | -33.94M | -29.15M | -29.07M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 95.9M | 89.4M | 78.56M | 73.81M | 68.91M |
| Total Liabilities | 6.29M | 6.86M | 6.23M | 7.64M | 9.94M |
| Total Equity | 89.61M | 82.55M | 72.33M | 66.17M | 58.97M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 60M | 47.13M | 38.48M | 123.02M | 89.4M |
| Total Liabilities | 5.46M | 19.85M | 21.4M | 15.56M | 6.86M |
| Total Equity | 54.55M | 27.28M | 17.08M | 107.46M | 82.55M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -25.35M | -31.71M | -10.47M | -19.15M | -28.71M |
| Investing | 46.58M | 59.43M | -8.09M | -5.32M | 2.34M |
| Financing | -7.86M | -7.91M | -28k | 5.04M | 10.02M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -23.09M | -29M | -28.95M | -28.18M | -31.71M |
| Investing | -9k | -32k | N/A | -107.37M | 59.43M |
| Financing | 73.21M | 16.72M | 20.78M | 111.31M | -7.91M |
| Market Cap | 314.38M |
| Price to Earnings Ratio | -10.76 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 9.66 |
| Price to Book Ratio | 3.79 |
| Dividend Yield | - |
| Shares Outstanding | 76.87M |
| Average Volume (1 week) | 759.16k |
| Average Volume (1 Month) | 4.68M |
| 52 Week Change | 209.85% |
| 52 Week High | 4.68 |
| 52 Week Low | 1.27 |
| Spread (Intraday) | 0.15 (3.66%) |
| Company Name | Trevi Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.trevitherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
